⚠️ Combining ibogaine with certain medications or substances can cause fatal cardiac arrhythmias, serotonin syndrome, or respiratory failure. Deaths have occurred when these interactions were not screened for in advance. Do not attempt ibogaine treatment without comprehensive medical screening and a full medication washout period supervised by a qualified clinician.

Why Drug Interactions with Ibogaine Are Especially Dangerous

Ibogaine is not a typical psychedelic. It is a potent alkaloid that acts on more than a dozen receptor systems simultaneously — including opioid, NMDA, sigma, and serotonin receptors — and it significantly prolongs the cardiac QT interval, which is the electrical recovery period of the heartbeat. A prolonged QT interval can degenerate into torsades de pointes, a potentially fatal ventricular arrhythmia. Any substance that also prolongs QT, inhibits ibogaine's metabolism, or competes on serotonergic pathways stacks risk in ways that can be fatal even in otherwise healthy adults.

Research published in Clinical Toxicology (Litjens & Brunt, 2016) identified cardiac events — most linked to drug interactions or undetected QT prolongation — as the leading cause of ibogaine-associated deaths. A 2021 review in Frontiers in Pharmacology (Corkery et al.) catalogued 19 fatalities and found polydrug use or undisclosed medications present in the majority of cases.

How Ibogaine Is Metabolized (Why This Matters)

Ibogaine is primarily metabolized by the liver enzyme CYP2D6 into noribogaine, its long-acting active metabolite. Noribogaine has a half-life of 24–72 hours and continues to affect cardiac conduction long after the acute psychedelic experience ends. Drugs that inhibit CYP2D6 cause ibogaine and noribogaine to accumulate to toxic levels. Separately, drugs that induce CYP3A4 can alter ibogaine's conversion pathway unpredictably. A urine and blood toxicology screen, along with CYP2D6 genotyping at some clinics, is standard practice at responsible treatment centers.

Absolute Contraindications: Medications That Must Be Stopped Before Ibogaine

QT-Prolonging Drugs

The following classes of medications independently prolong the QT interval. Combined with ibogaine, they create compounded risk of fatal arrhythmia. Most reputable clinical protocols require a washout period of at least 2 weeks (and in some cases 4–6 weeks) before ibogaine administration (MAPS Ibogaine Protocol, 2023; Multidisciplinary Association for Psychedelic Studies).

  • Antiarrhythmics: amiodarone, sotalol, quinidine, flecainide, dofetilide — these have very long half-lives; amiodarone's half-life can exceed 40 days
  • Antipsychotics: haloperidol, quetiapine, ziprasidone, chlorpromazine, risperidone, iloperidone
  • Antidepressants: tricyclics (amitriptyline, imipramine, clomipramine), citalopram, escitalopram — SSRIs that additionally prolong QT
  • Antibiotics: azithromycin, clarithromycin, moxifloxacin, levofloxacin, erythromycin
  • Antifungals: fluconazole, ketoconazole, itraconazole — also potent CYP3A4/2D6 inhibitors
  • Antiemetics: ondansetron (Zofran), domperidone, metoclopramide
  • Antihistamines: diphenhydramine (Benadryl) at high doses, astemizole, terfenadine
  • Methadone: independently prolongs QT significantly at therapeutic doses and has an extended half-life of 24–59 hours; requires an extended washout and medical supervision

Serotonergic Drugs — Serotonin Syndrome Risk

Ibogaine has serotonin reuptake inhibition properties. Combining it with other serotonergic agents risks serotonin syndrome, a life-threatening condition characterized by hyperthermia, muscle rigidity, clonus, and seizures. The following must be tapered and cleared before ibogaine:

  • SSRIs: fluoxetine (half-life up to 6 weeks including metabolite norfluoxetine — requires the longest washout of any SSRI, often 6 weeks minimum), sertraline, paroxetine (also a strong CYP2D6 inhibitor), escitalopram, fluvoxamine
  • SNRIs: venlafaxine, duloxetine, desvenlafaxine
  • MAOIs: phenelzine, tranylcypromine, selegiline, isocarboxazid — combination with ibogaine is considered absolutely contraindicated; wait at least 2 weeks after stopping a reversible MAOI and up to 4 weeks after irreversible MAOIs
  • Triptans: sumatriptan, rizatriptan
  • Tramadol: serotonergic opioid with additional seizure risk
  • Linezolid: antibiotic with MAOI activity
  • Lithium: can potentiate serotonergic effects and lower seizure threshold
  • St. John's Wort (Hypericum perforatum): herbal SSRI; often overlooked; requires washout

CYP2D6 Inhibitors — Ibogaine Accumulation Risk

These drugs block the primary enzyme that clears ibogaine, causing plasma levels to rise dangerously:

  • Paroxetine (Paxil) — one of the most potent CYP2D6 inhibitors in clinical use
  • Fluoxetine (Prozac)
  • Bupropion (Wellbutrin) — also lowers the seizure threshold independently
  • Duloxetine
  • Haloperidol
  • Cinacalcet
  • Terbinafine (antifungal)

Opioids — Acute Respiratory and Cardiac Risk

Ibogaine treats opioid use disorder in part by reducing opioid receptor sensitivity. However, opioids present a specific, documented danger when administered close in time to ibogaine:

  • Full agonist opioids (heroin, oxycodone, fentanyl, morphine, hydrocodone) used within 12–24 hours of ibogaine significantly increase risk of fatal respiratory depression and cardiac arrest. Ibogaine may precipitate withdrawal unpredictably, and noribogaine's long duration means opioid sensitivity is profoundly altered for days after treatment.
  • Fentanyl is particularly dangerous due to its high lipophilicity and potential to re-release from tissue stores. Urine fentanyl strips are insufficient for medical clearance — a quantitative blood fentanyl level is recommended by many clinical protocols.
  • Buprenorphine (Suboxone/Subutex): High receptor affinity means standard opioid washout periods may be insufficient. Many protocols require 48–72 hours minimum off buprenorphine before ibogaine, with some requiring up to 7 days for higher doses. A precipitated withdrawal during the ibogaine experience — characterized by extreme agitation — increases cardiovascular stress.
  • Methadone: Listed under QT section above; dual cardiac and metabolic risk.

Stimulants

  • Cocaine: Causes coronary vasospasm and independently prolongs QT; combined with ibogaine, documented fatal cardiac events have occurred. Must be abstained from for at least 24–48 hours, ideally 72 hours.
  • Methamphetamine/amphetamines: Increase cardiac stress and interfere with ibogaine's noradrenergic effects.
  • MDMA (ecstasy): Strongly serotonergic; combined risk of serotonin syndrome and QT prolongation. Minimum washout of 2 weeks recommended.
  • Prescription stimulants (Adderall, Ritalin): Must be disclosed and typically held for at least 48 hours prior.

Alcohol and CNS Depressants

  • Alcohol: Acute intoxication combined with ibogaine increases respiratory depression risk and unpredictably alters cardiovascular response. Many facilities require 24–72 hours of abstinence minimum. Chronic heavy use causes hepatic damage, reducing ibogaine's safe metabolism.
  • Benzodiazepines (Xanax, Valium, Klonopin): Often co-administered in emergencies to manage ibogaine-induced agitation or seizure. However, chronic benzodiazepine dependence requires medical tapering before treatment — abrupt cessation risks life-threatening withdrawal seizures separately from ibogaine.
  • Gabapentin/Pregabalin: CNS depressants with complex interactions; require disclosure.
  • GHB/GBL: Dangerous cardiac depressants; require at least 24-hour abstinence.

Cannabis

Cannabis is not an absolute contraindication, but heavy use can obscure a participant's mental health baseline, and THC has mild QT effects. Most protocols request abstinence for 24–48 hours prior and do not permit use during the treatment window.

Medical Condition Contraindications

Drug interactions are not the only source of danger. The following pre-existing conditions are considered absolute or strong contraindications in most evidence-based clinical protocols (Global Ibogaine Therapist Alliance Clinical Guidelines, 2015; Mash et al., 2018 in Frontiers in Pharmacology):

  • Prolonged QTc interval at baseline: A QTc above 440 ms in men or 450 ms in women is a contraindication at most reputable centers. Some use a cutoff of 430 ms. A 12-lead ECG within 24–48 hours of treatment is mandatory.
  • Structural heart disease: Coronary artery disease, cardiomyopathy, congenital heart defects, history of myocardial infarction
  • Personal or family history of sudden cardiac death or Brugada syndrome
  • Uncontrolled hypertension
  • Severe liver disease or cirrhosis: Ibogaine is hepatically metabolized; liver impairment causes dangerous accumulation
  • Active psychosis or schizophrenia spectrum disorder: Ibogaine can precipitate or worsen psychotic episodes; it is not appropriate for these populations
  • Bipolar disorder Type I: Strong relative contraindication; manic episodes can be triggered
  • Active seizure disorder: Ibogaine lowers the seizure threshold
  • Pregnancy: Ibogaine is a uterine stimulant and is teratogenic in animal studies; absolutely contraindicated
  • Severe kidney disease: Alters clearance of noribogaine
  • Electrolyte imbalances (hypokalemia, hypomagnesemia): Low potassium and magnesium independently prolong QT; must be corrected before treatment via bloodwork

Required Pre-Treatment Screening (What Responsible Clinics Do)

Any reputable ibogaine treatment center should require all of the following before administration:

  • 12-lead ECG with QTc measurement, ideally within 24 hours of dosing
  • Comprehensive metabolic panel (CMP) — liver function, kidney function, electrolytes
  • Complete blood count (CBC)
  • Urine drug screen — including fentanyl-specific testing
  • Blood quantitative fentanyl level if fentanyl exposure is suspected
  • Full medication disclosure — including OTC medications, supplements, and herbal products
  • Psychiatric evaluation — screening for psychosis, bipolar disorder, suicidality
  • Vital signs and physical examination
  • Pregnancy test for individuals who could become pregnant

Facilities that skip or rush any of these steps should be considered unsafe. Cardiac monitoring via continuous pulse oximetry and ECG during the experience, and crash cart availability, are additional markers of a responsible facility.

Documented Consequences of Ignoring These Protocols

The real-world cost of ignored drug interactions is documented:

  • A 2012 case report in Forensic Science International described a fatality in a 52-year-old male who had undisclosed methadone in his system; autopsy confirmed torsades de pointes.
  • Corkery et al. (2004, updated analyses through 2021) found that in the majority of ibogaine-associated deaths where toxicology was available, other substances — most commonly opioids, alcohol, or QT-prolonging drugs — were present.
  • Several deaths have been attributed to self-administration of ibogaine purchased online, without any screening or supervision, by individuals actively using opioids or taking antidepressants.
  • A peer-reviewed case series (Meisner et al., 2016, Journal of Medical Toxicology) described patients surviving ibogaine-related cardiac events specifically because emergency ECG monitoring and defibrillation were immediately available — underscoring why facility readiness is non-negotiable.

What to Tell Your Prescribing Doctor

If you are considering ibogaine treatment and are currently taking prescribed medications, the safest course of action involves these concrete steps:

  1. Bring a complete, written list of every medication, supplement, and substance to the ibogaine provider's intake team.
  2. Request that the ibogaine provider communicate directly with your prescribing physician about safe tapering timelines. Do not self-taper psychiatric or cardiac medications.
  3. Ask specifically: "What is the required washout period for each of my medications, and how will you confirm clearance before treatment?"
  4. Request a pre-treatment ECG and ask to see your QTc value in writing before you travel to a facility.
  5. Do not withhold any substance use history — including substances you are embarrassed about or that are illegal. Providers are focused on your safety, not your legal exposure.

Frequently Asked Questions

It depends on the specific antidepressant. Most SSRIs require a minimum washout of 2 weeks. Fluoxetine (Prozac) is the critical exception — its active metabolite norfluoxetine has a half-life of up to 2 weeks on its own, meaning the full drug may not clear for 4–6 weeks after your last dose. Paroxetine (Paxil) must also be tapered carefully because it is both serotonergic and a potent CYP2D6 inhibitor, and abrupt discontinuation causes severe withdrawal. MAOIs require at least 2–4 weeks depending on whether they are reversible or irreversible. Never stop an antidepressant abruptly — work with your prescribing physician on a supervised taper plan coordinated with your ibogaine provider.
No. Buprenorphine's very high opioid receptor affinity means that even after stopping it, receptor occupancy persists for longer than shorter-acting opioids. Most clinical protocols require a minimum of 48–72 hours off buprenorphine before ibogaine, and some require up to 7 days for people on higher doses (e.g., above 8 mg/day). Dosing ibogaine while buprenorphine is still active significantly increases the risk of precipitated withdrawal, which generates extreme cardiovascular and psychological stress during an already demanding treatment. A responsible facility will confirm cessation with urine and blood testing, not just patient self-report.
No. Acute alcohol intoxication combined with ibogaine increases respiratory depression risk and creates unpredictable cardiovascular effects. Most reputable facilities require a minimum of 24–72 hours of alcohol abstinence before treatment. People with chronic heavy alcohol dependence face an additional concern: their liver function may be compromised, slowing ibogaine clearance and increasing toxicity risk. Additionally, abrupt alcohol cessation in physically dependent individuals can itself cause life-threatening withdrawal seizures — which must be managed separately before ibogaine is considered.
This is one of the highest-risk scenarios in ibogaine treatment, and deaths have occurred. Fentanyl is highly lipophilic, meaning it deposits into fatty tissue and can re-release into circulation hours after use — this is called "fentanyl redistribution." During the ibogaine experience, which lasts 18–36 hours, a surge of fentanyl releasing from tissue stores can cause fatal respiratory depression. Standard urine fentanyl test strips are not sufficient to rule out systemic fentanyl; quantitative blood plasma fentanyl levels are required. Many ibogaine clinics currently treating opioid use disorder have specific fentanyl protocols and may use extended pre-treatment observation periods. If a facility does not ask specifically about fentanyl and test for it by blood, that is a serious red flag.
QT prolongation refers to a lengthening of the electrical recovery period of the heart between beats, measured on an electrocardiogram (ECG). When this interval becomes too long — particularly above 500 ms — the heart becomes vulnerable to a dangerous arrhythmia called torsades de pointes, which can rapidly degenerate into ventricular fibrillation and cardiac arrest. Ibogaine itself prolongs QTc, typically by 20–40 ms in clinical settings. Many common medications — including methadone, certain antibiotics, antipsychotics, and some antidepressants — also prolong QTc independently. When stacked together, these effects multiply. Low potassium or magnesium (common in people with substance use disorders due to poor nutrition) further compounds the risk. This is why a baseline ECG and electrolyte panel are non-negotiable safety requirements before ibogaine dosing.
Yes. Several commonly available products carry meaningful risks. St. John's Wort is an herbal serotonin reuptake inhibitor and can contribute to serotonin syndrome; it should be stopped at least 2 weeks before treatment. Diphenhydramine (Benadryl), found in many sleep aids and allergy products, has QT-prolonging effects at higher doses. Pseudoephedrine and phenylephrine (decongestants) are sympathomimetics that increase cardiovascular strain. 5-HTP, a serotonin precursor sold as a supplement, increases serotonergic load. Grapefruit juice inhibits CYP3A4 and should be avoided. Always disclose everything — including vitamins, protein powders, and herbal teas — to the medical team at your facility.

Sources

  • Litjens, R.P.W. & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302. https://doi.org/10.3109/15563650.2016.1138226
  • Corkery, J.M., Schifano, F., & Ghodse, A.H. (2012). Ibogaine-related deaths and near-death experiences: A case series. Human Psychopharmacology, 27(5). https://doi.org/10.1002/hup.2246
  • Mash, D.C. et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529. https://doi.org/10.3389/fphar.2018.00529
  • Meisner, J.A. et al. (2016). Ibogaine-associated cardiac arrest and death: Case report and review of the literature. Journal of Medical Toxicology, 12(2), 214–219. https://doi.org/10.1007/s13181-015-0525-8
  • Global Ibogaine Therapist Alliance (GITA). (2015). Clinical Guidelines for Ibogaine-Assisted Detoxification. https://www.ibogainealliance.org/guidelines/
  • Koenig, X. & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules, 20(2), 2208–2228. https://doi.org/10.3390/molecules20022208
  • Brown, T.K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6(1), 3–16.
  • MAPS Ibogaine Research Protocol Documentation (2023). Multidisciplinary Association for Psychedelic Studies.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.